Wealth Enhancement Advisory Services’s Definium Therapeutics DFTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$374K	Buy	+7,952	New	+$197K	﹤0.01%	2979
2026 Q1	–	Sell	-13,718	Closed	-$185K	–	3773
2025 Q4	$185K	Buy	13,718 +366	+3%	+$4.53K	﹤0.01%	3294
2025 Q3	$160K	Sell	13,352 -84	-0.6%	-$783	﹤0.01%	3214
2025 Q2	$96.3K	Sell	13,436 -102	-0.8%	-$671	﹤0.01%	3142
2025 Q1	$79.2K	Sell	13,538 -12	-0.1%	-$86	﹤0.01%	2802
2024 Q4	$94.3K	Buy	13,550 +3,350	+33%	+$23K	﹤0.01%	2810
2024 Q3	$58K	Buy	+10,200	New	+$70.9K	﹤0.01%	2608

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wealth Enhancement Advisory Services's DFTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 7,952 shares worth $374K. The stake represents ﹤0.01% of the portfolio and ranks #2979 among its holdings. This is a return to the name: Wealth Enhancement Advisory Services previously reported a position in DFTX as recently as Q4 2025.

Wealth Enhancement Advisory Services first reported a position in DFTX in Q3 2024 and has held it in 7 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Wealth Enhancement Advisory Services held 7,952 shares of Definium Therapeutics worth $374K as of Q2 2026.
Definium Therapeutics was a new Wealth Enhancement Advisory Services position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2979 holding.
Wealth Enhancement Advisory Services first reported a position in Definium Therapeutics in Q3 2024 and has held it in 7 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.